In silico neo-antigen detection in high grade pediatric brain tumors utilizing RNA-seq and WGS

Email Principal Investigator
Atypical teratoid/rhabdoid tumor (AT/RT)

About this


Immunotherapy holds great promise in the treatment of pediatric central nervous system tumors. This is especially true in high grade tumor pathologies (high grade glioma, DIPG, ATRT, medulloblastoma, etc.) where the underlying biology does not seem to involve targetable driver mutations, but rather tumor biology is heavily influenced and driven by epigenetic changes that influence gene expression and regulation. Without obvious pharmacologic targets, immunotherapies have the potential to play a major role in combating this type of tumor. A crucial first step in the development of an immunotherapy approach, especially adoptive T-cell therapies, is the identification of tumor neo-antigens.

Ask The


Ask the scientists

What are the goals of this project?

The goal of this project is to identify new antigens in patients with high-grade pathologies using silico techniques as well as to HLA type matching

What is the impact of this project?

The initial data from this study will hopefully lead to the proof of concept that patient-specific tumor genome and transcriptome data can be used to design patient-specific and/or disease-specific immunotherapy targets in a real-time manner in these tumor types. The neo-antigens that are identified will also be used in pre-clinical studies that aim to construct novel targets for immunotherapies (mainly chimeric antigen receptor development).

Specimen Data

The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.

Explore the data in these informatics portals